Clock Ticking for Pharma: India’s Drug Regulator to Reject Unresponsive Applications Within 30 Days

NEW DELHI — In a major move to streamline India’s healthcare regulatory landscape, the Central Drugs Standard Control Organisation (CDSCO) has issued a final ultimatum to pharmaceutical companies and medical device manufacturers. Effective May 4, 2026, the national regulator announced that any applications pending on its digital SUGAM portal due to unanswered queries will be summarily rejected—and application fees forfeited—if responses are not filed within a strict 30-day window.

The directive targets a massive backlog of “zombie” files—applications for drugs, medical devices, biologics, and cosmetics that have languished in the system for years because companies failed to provide necessary information. For the Indian public, the move promises a more efficient pipeline for new treatments, while for the industry, it signals the end of administrative leniency.

Clearing the Regulatory Bottleneck

The SUGAM portal serves as the single-window interface for all regulatory submissions to the CDSCO. While the platform was designed to usher in transparency and speed, it has become cluttered with inactive files. According to the public notice, some of these applications have remained dormant since 2016.

Under the new policy, the CDSCO is implementing a rigorous “three-reminder” protocol:

1. Initial Reminders: Applications that have remained pending for more than two years have already been subjected to a series of three reminders.

2. Final Notice: The May 4 notice serves as the final 30-day “grace period.”

3. Automatic Rejection: If no response is received within this month-long window, the application will be closed, and the significant fees paid during submission will be kept by the government.

“This is not just about housekeeping; it’s about system integrity,” says a regulatory consultant familiar with the matter. “When thousands of inactive files sit in the portal, it slows down the review process for legitimate, life-saving medicines that are ready for the market.”

Why the Move Matters to Public Health

While a regulatory deadline might seem like “inside baseball” for the pharmaceutical industry, the implications for public health are significant. The CDSCO oversees the safety, efficacy, and quality of every medicine and medical device sold in India.

1. Faster Access to Innovation

By clearing out inactive applications, regulatory officers can focus their resources on active files. This could theoretically reduce the “time-to-market” for new therapies, including domestic generics and innovative foreign drugs.

2. Accountability in Safety

Often, a “query” from the CDSCO is a request for more safety data or clarification on manufacturing standards. When a company leaves these queries unanswered for years, it leaves a potential product in a state of clinical limbo. This move forces manufacturers to either stand by their data or withdraw from the race.

3. Enhancing “Ease of Doing Business”

A streamlined regulatory process is essential for India’s ambition to remain the “Pharmacy of the World.” Predictable timelines attract global investment, which often leads to more clinical trials and earlier access to global medical breakthroughs for Indian patients.

Expert Perspectives: A Necessary “Administrative Reset”

Regulatory affairs specialists view the 30-day deadline as a necessary, if blunt, instrument. Many in the industry acknowledge that some companies have used the lack of a “hard stop” to keep applications alive indefinitely without meeting safety or technical requirements.

“Timely compliance is no longer optional; it is a core component of market access strategy,” notes a recent briefing from CliniExperts, a leading regulatory advisory firm. “Organizations need to realize that silence is now a definitive ‘no’ in the eyes of the regulator.”

However, some experts caution that the move could be a double-edged sword. If a company misses a notification due to technical glitches in the SUGAM portal or changes in staffing, a scientifically sound medicine could be rejected on a technicality. This has led to calls for a clear “appeals process” for exceptional cases, though the current CDSCO notice does not explicitly outline one.

Statistical Context and Scope

While the CDSCO has not released the exact number of applications currently facing the axe, industry reports from The Economic Times and Pharmabiz suggest that the backlog spans multiple divisions, including:

• New Drugs and Clinical Trials

• Medical Devices and Diagnostics

• Biologicals and Vaccines

• Cosmetic Registrations

The forfeiture of fees is a particularly strong deterrent. Depending on the category, application fees can range from several thousand to several lakh rupees. For large pharmaceutical firms, this is a financial nuisance; for smaller biotech startups, a forfeited fee and rejected application could be a significant setback.

What This Means for Consumers and Applicants

For Health-Conscious Consumers:

There is no immediate change to the medicines currently on your pharmacy shelves. However, this policy ensures that the “pipeline” of future drugs is being managed by a more disciplined regulator. It reduces the risk of outdated or incomplete applications eventually sliding through a congested system.

For Industry Applicants:

The CDSCO’s message is clear: Check your dashboard.

• Audit Pending Queries: Immediately review all submissions on the SUGAM portal.

• Update Contact Info: Ensure that the registered email address is monitored daily.

• Act Within 30 Days: If a query is pending, a response—even an interim one—is vital to prevent the file from being permanently closed.

The Road Ahead

This “administrative enforcement” marks a shift in how India handles medical bureaucracy. By moving away from an indefinite waiting period to a structured, 30-day expiration, the CDSCO is aligning itself with international standards used by the US FDA and the European Medicines Agency (EMA).

As the deadline approaches in early June 2026, the industry will be watching closely to see if the CDSCO follows through with mass rejections. For now, the “Pharmacy of the World” is getting a long-overdue digital spring cleaning.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Economic Times Pharma. “CDSCO mandates 30-Day Window to answer Queries on Drug Applications,” published May 5, 2026.